why choose us

First received: October 12, 2023

Clinical Trial: Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Essential Tremor

Study Type: INTERVENTIONAL


Official Title: Phase 3, Decentralized, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Randomized Withdrawal, and Long-term Safety Study to Evaluate the Efficacy and Safety of Ulixacaltamide (PRAX-944

Brief Summary: The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor.The main question it aims to answer is:• Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor?Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks.After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study and…

Read more